A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata
Status:
Completed
Trial end date:
2017-11-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether tralokinumab can be a helpful treatment for
alopecia areata. This is a randomized, double-blind, placebo-controlled pilot study of a
total of 30 subjects with moderate to severe alopecia areata involving 30-100% of the scalp.
Expected is 50% of these subjects to have concomitant alopecia areata (AA) and atopic
dermatitis (AD). Subjects with AA alone (15 subjects) will be randomized (2:1) to either
receive tralokinumab or placebo via subcutaneous injection every 2 weeks for 24 weeks.
Subjects with concomitant alopecia areata and atopic dermatitis (15 subjects) will be
randomized separately in a 2:1 ratio to receive tralokinumab or placebo via subcutaneous
injection every 2 weeks for 24 weeks.